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ABBREVIATIONS LIST. DBP: vitamin D binding protein, VDR: vitamin D 
receptor, VDRE: vitamin D response element 
 
ABSTRACT An improved synthetic route to des-side chain analogues of 
1α,25-dihydroxyvitamin D3 with substituents at C-18 and their biological 
activity is reported. These analogues displayed significant antiproliferative and 
prodifferentiating effects with a greatly reduced calcemic profile. The crystal 
structure of the human vitamin D receptor (hVDR) complexed to one of these 
analogues, 20(17 18)-abeo-1α,25-dihydroxy-22-homo-21-norvitamin D3 (2a), 
revealed that the side chain introduced at position C-18 adopts the same 
orientation in the ligand binding pocket as the side chain of 1α,25-
dihydroxyvitamin D3.  
Introduction 
The growth-inhibitory, prodifferentiating, and immunomodulatory activity of 
1α,25-dihydroxyvitamin D3 (1a, Fig. 1), the hormonally active form of vitamin 
D3 (1b), opens perspectives for the use of this compound in cancer, psoriasis, 
and immune-related disorders such as multiple sclerosis and inflammatory 
bowel disease. However, the therapeutic applicability of 1α,25-
dihydroxyvitamin D3 is limited due to hypercalcemia.
1
 Therefore, it remains a 
major challenge to design and synthesize analogues of 1α,25-dihydroxyvitamin 
D3 that have the best possible balance between the advantageous 
antiproliferative and prodifferentiating effects and the adverse calcemic 
activity. 
One of our research strategies is focused on the synthesis of 1α,25-
 3 
dihydroxyvitamin D3-analogues with side chains attached to the angular C-18 
methyl group. Most of the reported C-18 substituted analogues are linked to C-
18 through an oxygen atom and carry residual groups at C-17.
2
 We recently 
reported the synthesis of novel 1α,25-dihydroxyvitamin D3-analogues in which 
side chains homologous to that of the natural hormone are linked to C-18 
through a C-C bond and that have no substituents on C-17.
3
 However, the 
structural analysis and biological activity of these compounds was not yet 
reported. In this paper we present an improved synthetic route to two of these 
analogues, 20(17→18)-abeo-1α,25-dihydroxy-22-homo-21-norvitamin D3 (2a, 
Fig. 1) and 20(17→18)-abeo-1α,25-dihydroxy-22,23-dihomo-21-norvitamin D3 
(2b). A structural study of the 7-membered C-18 side chain analogue 2a 
complexed to hVDR was performed in order to investigate the binding mode of 
this newly introduced side chain at C-18. Furthermore, the biological activity 
profile of these analogues was determined in several cancer cell lines.  
Results and discussion 
Chemistry. The target compounds 2a and 2b were synthesized by modified 
procedures of our previous strategy
3
 as outlined in Scheme 1. The replacement 
of the tert-butyldimethylsilyl protecting group by the triethylsilyl group was 
thought to have benefits at the final deprotection-purification stage. To set the 
vitamin D triene system corresponding to 2a, we coupled hydroxyketone 4 with 
the lithium anion of phosphine oxide 3 in THF at -78 ºC to obtain protected 
vitamin D3 analogue 2a-TES in 85% yield. Desilylation of 2a-TES took place 
cleanly using pyridinium fluoride to give the desired vitamin D3 analogue 2a in 
high yield. This result validates the use of phosphine oxide 3 in the syntheses of 
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future vitamin D3 analogues following Lythgoe’s Wittig-Horner approach.
4
 The 
synthesis of 2b commenced with known carboxylic acid 5,
3
 which was 
converted to alcohol 6 in 24% yield by a seven-step sequence involving 
reduction of the carboxylic group, tosylation, displacement of the resulting 
tosylate with sodium cyanide, reduction of the resulting nitrile to the 
homologated aldehyde, methylation, oxidation and methylation of the resulting 
ketone. Desilylation of 6 followed by hydrogenation of the double bond and 
oxidation of the secondary hydroxyl group provided ketone 7 in 82% yield. 
Coupling of ketone 7 with the lithium anion of phosphine oxide 3 afforded, 
after desilylation, the desired eight-membered vitamin D side-chain analogue 
2b in 78% yield over the three steps (12 steps from 5, 15.7% overall yield). 
Structural analysis. A structural study of the hVDR-2a complex was 
performed to gain more insight in the interaction of the 2a analogue with the 
VDR. In this complex, the protein adopted the canonical conformation of all 
previously reported structures of VDR bound to agonist and superagonist 
ligands with helix H12 folded in the agonistic position.
5
 The 7-membered side 
chain introduced at position C-18 adopted the same orientation in the pocket. 
An adaptation of its conformation was observed to maintain the hydrogen 
bonds forming the anchoring points. Compared with the structure of hVDR- 
1α,25(OH)2D3 complex, the atomic coordinates of hVDR bound to compound 
2a showed root-mean-square deviation of 0.25 Å of all Cα atoms. The sizes of 
the ligands were 391 and 396 Å
3
 for analogue 2a and 1α,25(OH)2D3, 
respectively. The volume of the ligand binding cavity was 638 and 673 Å
3
 and 
the ligand occupied 59% and 61% of the pocket for 2a and 1α,25(OH)2D3, 
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respectively. The A and secoB rings of the C-18 side chain analogue 2a 
presented conformations similar to those of the natural ligand (Fig. 2A-B). As a 
consequence of the modified side chain, the C and D rings were shifted by 
around 0.4 Å. The distance between the 1-hydroxy and the 25-hydroxy groups 
varied from 13.1 Å for 1α,25(OH)2D3 to 12.8 Å for analogue 2a complex. All 
the residues of VDR forming the binding pocket adopted the same 
conformation as those of the VDR/1α,25(OH)2D3 except for the side chain of 
Ile271 (H5). The interactions between the ligand and the receptor involved 
hydrophobic contacts and electrostatic interactions. The hydroxyl groups made 
the same hydrogen bonds as VDR/1α,25(OH)2D3 complex, 1-OH with Ser237 
(H3) and Arg274 (H5), 3-OH with Tyr143 (H1) and Ser278 ( 0), and the 25-
OH with His305 (loop H6-H7) and His397 (H11). Because of the modification 
of the ligand, the side chain of compound 2a took another pathway in the 
pocket and made additional contacts with the CB atom of Leu230 (H3) at 3.9 Å 
of C-20 and 3.6 Å of C-22 atom, respectively. Its side chain, however, lost a 
contact with the CD2 atom of Leu309 (H7) at 3.8 Å of C-21 for 1α,25(OH)2D3 
(Fig. 2C). The elongated side chain of 2a induced contacts between the C-26 
and Leu404 (H11), the C-26 and Leu414 (loop H11-H12), C-27 and Phe422 
(H12) at the end of the ligand. A C  atom of His305 was shifted by 0.4 Å to 
maintain the hydrogen bonds with the hydroxyl group.  
To confirm the crystallographic data, several VDR mutants were used to 
investigate the capacity of compound 2a to transactivate a vitamin D response 
element (VDRE)-containing reporter construct. 1α,25(OH)2D3 as well as the 7-
membered C-18 side chain analogue 2a were unable to transactivate the 
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reporter construct when cells were transfected with VDRs carrying either the 
Leu233Ala, Ile271Ala, Arg274Ala, Trp286Ala, His397Ala, or Tyr401Ala 
mutation (Fig. 3). The transactivation potency of 1α,25(OH)2D3 was moderately 
reduced when cells were transfected with the VDR mutants Val234Ala, 
Ile268Ala, Val300Ala, and His305Ala (50% of the activity of wild type VDR), 
whereas transfection with the mutants Ser275Ala and Ser278Ala had little 
effect on the transactivation capacity of 1α,25(OH)2D3. Introduction of a 7-
membered side chain at C-18 rendered analogue 2a less potent than 
1α,25(OH)2D3 in transactivating a VDRE-containing reporter construct in cells 
transfected with the VDR mutants Ile268Ala, Ser275Ala, Val300Ala, and 
His305Ala. These findings were in agreement with the crystal structure and 
suggested that interactions with these amino acids became more critical when a 
side chain was introduced at C-18 instead of at position C-17. The 
transactivating capacity of the VDR mutant Val234Ala became more potent in 
cells that were incubated with compound 2a, which confirmed crystallographic 
data that showed a weaker interaction between this amino acid and the side 
chain of this 2a analogue. 
Heterodimerization with RXR. To assess whether VDR bound to DSA was 
able to heterodimerize with RXR, we monitored its interaction with by ESI-MS 
under non-denaturating conditions. Addition of fivefold molar excess of 2a in 
the heterodimer VDR/RXR LBDs resulted in the appearance of a novel series 
of mass/charge (m/z) ions corresponding to a fully bound VDR-2a/RXR.
6
 The 
different conformation of the VDR-bound 2a analogue does not affect the 
VDR/RXR heterodimer stability. We then monitored by ESI-MS the 
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recruitment of the SRC-1 NR2 coactivator peptide to VDR-2a/RXR complex 
(data not shown) that was similar to VDR- 1 ,25(OH)2D3/RXR.  
Biological evaluation. Despite the fact that the analogue 2a fitted well in the 
VDR binding pocket and that the hydrogen bonds, which form the anchoring 
points, were maintained, the affinity of compound 2a for pig VDR was greatly 
reduced (2.5% of the affinity of 1α,25(OH)2D3) (Table 1). Also the binding to 
the transport protein vitamin D binding protein (hDBP) was significantly 
reduced (10% of the affinity of 1α,25(OH)2D3). Homologation of the side chain 
in compound 2b further decreased the binding affinity to DBP and VDR (1.3% 
and 4% of the affinity of 1α,25(OH)2D3, respectively). The low affinity for the 
DBP can be explained by attachment of the 2a and 2b side-chain fragments to 
the C18 that orientates the side-chain hydroxyl groups towards the -face of the 
CD rings. The lower affinity of 2a and 2b for DBP may also explain their 
reduced calcemic activity. Nothwithstanding this low affinity for VDR, but in 
accordance with the transactivation results, the 7-membered C-18 side chain 
analogue 2a was as potent as 1α,25(OH)2D3 in reducing the proliferation of 
human breast adenocarcinoma MCF-7 cells (Table 1). Addition of an extra C-
atom in the side chain in compound 2b decreased the growth-inhibitory 
potential of this analogue because 3-fold higher concentrations of this 
compound were required to obtain a 50% decrease in proliferation. The ability 
to induce cell differentiation was investigated in human colon cancer SW480-
ADH cells, which upon incubation with 1α,25(OH)2D3 undergoes epithelial 
differentiation with increased adhesiveness as a result of a drastic change in 
their pattern of gene expression that includes the induction of E-cadherin, 
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occludin and several other adhesion proteins.
7
 Both C-18 side chain analogues 
induced a similar morphological change as 1α,25(OH)2D3, promoting the 
formation of compact epithelioid cell islands, but again the analogue with the 
longer side chain (2b) was less efficient (Fig. 4A). Likewise, compound 2a and 
1α,25(OH)2D3 were equipotent in increasing the cellular content of E-cadherin, 
a hallmark of the differentiated phenotype, while the 2b analogue was less 
potent (Fig. 4B). In agreement with this, analogue 2a as well as 1α,25(OH)2D3, 
but not analogue 2b, increased VDR expression (Fig. 4B). 
Interestingly, introduction of a side chain at position C-18 led to an interesting 
decrease of calcemic activity. Indeed, when compared to 1α,25(OH)2D3, at least 
600-fold higher doses of the 7- or 8-membered C-18 side chain analogues could 
be administered on a daily basis in NMRI vitamin D-replete mice (Table 1). 
This low calcemic activity makes these compounds, especially compound 2a, 
appealing for therapeutic application. 
Conclusions  
We describe improved syntheses of two des-side chain analogues of 1α,25-
dihydroxyvitamin D3 with substituents at C-18. In the VDR structural study we 
demonstrated that the 7-membered side chain introduced at position C-18 in 
compound 2a adopted the same orientation in the ligand binding pocket as the 
side chain of 1α,25-dihydroxyvitamin D3 with maintenance of the hydrogen 
bonds that form the anchoring points of the ligand. Mutational analysis 
confirmed the interactions of compound 2a with the amino acids lining the 
VDR-ligand binding pocket as determined in the crystallization study. Despite 
the fact that analogue 2a fitted well in the VDR binding pocket, it displayed a 
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weak binding to VDR and homologation of the side chain further decreased the 
affinity. Nevertheless both des-side chain analogues of 1α,25-dihydroxyvitamin 
D3 possessed significant antiproliferative and prodifferentiating properties with 
greatly reduced calcemic effects. This biological profile makes these analogues, 
and especially compound 2a, potential candidates for the treatment of 
hyperproliferative disorders such as breast or colon cancer. 
 
Experimental section 
Chemistry.
8
 In addition to NMR, HPLC analysis was used to determine the 
purity (>95%) of vitamin D analogues. 
20(17 18)-abeo-3-(Triethylsilyl)-1 -[(triethylsilyl)oxy]-25-hydroxy-22-
homo-21-norvitamin D3 (2a-TES). A solution of n-BuLi (0.45 mL, 1.14 
mmol, 2.5 M in hexanes) was added to a solution of phosphine oxide 3 (0.702 
g, 1.204 mmol) in dry THF (8 mL) at -78 °C. The deep red solution was stirred 
for 1 h. A solution of ketone 4 (0.063 g, 0.277 mmol) in dry THF (8 mL) was 
added dropwise. The reaction mixture was stirred in the dark at -78 °C for 3 h 
and at -30 °C for 4 h. H2O (0.5 mL) was added and the resulting mixture was 
concentrated to give a residue which was dissolved in Et2O (100 mL). The 
combined organic phase was washed with saturated NaHCO3 (20 mL), brine 
(3x20 mL), H2O (60 mL), dried, filtered, and concentrated. The residue was 
purified by flash chromatography (SiO2, 2x15 cm, 6-12% Et2O-hexanes) to 
give the protected analogue 2a-TES [0.125 g, 85%, Rf = 0.8 (30 % EtOAc-
hexanes), colorless oil]. 
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20(17 18)-abeo-1α,25-Dihydroxy-22,23-dihomo-21-norvitamin D3 (2a). 
HF-pyridine complex (10 drops) was slowly added to a solution of 2a-TES 
(0.125 g, 0.194 mmol) in dry CH3CN (6 mL), dry CH2CL2 (4 mL) and dry Et3N 
(3 mL). The reaction mixture was stirred in the dark at rt for 1 h. Saturated 
NaHCO3 (30 mL) was added slowly and the aqueous layer was extracted with 
Et2O (4x20 mL). The combined organic layer was washed with brine (2x25 
mL), dried, filtered and concentrated. The residue was purified by flash 
chromatography (SiO2, 1.5x15 cm, 10-12% i-PrOH-hexanes) to give 2a [0.079 
g, 98%, Rf = 0.4 (20% i-PrOH-hexanes), white solid]. 
20(17 18)-abeo-3-(Triethylsilyl)-1 -[(triethylsilyl)oxy]-25-hydroxy-22,23-
dihomo-21-norvitamin D3 (2b-TES). A solution of n-BuLi (0.41 mL, 1.02 
mmol, 2.5 M in hexanes) was added to a solution of phosphine oxide 3 (0.627 
g, 1.076 mmol) in dry THF (5 mL) at -78 °C. The deep red solution was stirred 
for 1 h. A solution of ketone 7 (0.050 g, 0.17 mmol) in dry THF (5 mL) was 
added dropwise. The reaction mixture was stirred in the dark at -78 °C for 2 h 
and at -55 °C for 4 h. H2O (0.5 mL) was added. Concentration gave a residue 
which was dissolved in Et2O (100 mL). The combined organic phase was 
washed with saturated NaHCO3 (20 mL), saturated NaCl (3x20 mL), H2O (60 
mL), dried, filtered, and concentrated. The residue was purified by flash 
chromatography (SiO2, 2x15 cm, 6-12% Et2O-hexanes) to give protected 
analogue 2b-TES [0.091 g, 82%, Rf = 0.8 (30 % EtOAc-hexanes), colorless 
oil]. 
20(17 18)-abeo-1α,25-Dihydroxy-22,23-dihomo-21-norvitamin D3 (2b). 
HF-pyridine complex (10 drops) was slowly added to a solution of 2b-TES 
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(0.085 g, 0.136 mmol) in dry CH3CN (3 mL), dry CH2Cl2 (1 mL) and dry Et3N 
(1 mL). The reaction mixture was stirred in the dark at rt for 1.5 h. Saturated 
NaHCO3 (30 mL) was added slowly and the aqueous layer was extracted with 
Et2O (4x20 mL). The combined organic layer was washed with brine (2x25 
mL), dried, filtered and concentrated. The residue was purified by flash 
chromatography (SiO2, 1.5x15 cm, 10-12% i-PrOH-hexanes) to give 2b
 
[0.05 g, 
95%, Rf = 0.5 (30% i-PrOH-hexanes), white solid]. 
Details on the syntheses of compounds 3, 6a, 6b, 6c, 6d, 6e, 6f, 6g, 6, 7a and 7 
are described in the Supplementary Material. 
 
Structural analysis of hDVR complexed to compound 2a, biological activity 
and electrospray ionization mass spectrometry are shown in the 
supplementary material. 
Figure legends 
Figure 1. Chemical structure of 1α,25(OH)2D3 and 20(17 18)-abeo-
analogues. 
Figure 2. Conformation of the VDR-bound 2a analogue. (A) Compound 2a is 
shown it its FO-FC electron density omit map contoured at 3.0 . The ligand is 
shown in stick representation with carbon and oxygen atoms in green and red, 
respectively. (B) A stereo view of the ligand conformations of 1α,25(OH)2D3 
(red) and compound 2a (blue) in their ligand binding pockets. (C) 
Superposition of the VDR∙2a (gray) and VDR∙1α,25(OH)2D3 (yellow) 
complexes. The view is restricted to the region of the protein (H3, H7, H11, 
and H12), which contains the side chain of the ligand. Only residues closer 
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than 4.0 Å are shown. Leu309 and Tyr401for the compound 2a complex and 
Leu230, Leu404, Leu414, and Phe422 for the∙1α,25(OH)2D3 complex are 
shown for comparisons. The ligands are shown in stick representation in blue 
for analogue 2a and red for 1α,25(OH)2D3, respectively. The hydrogen bonds 
formed by the 25-OH groups are shown in blue (compound 2a) and red 
(1α,25(OH)2D3) dashed lines.  
Figure 3. Transactivating potency of different VDR point mutants in COS-1 
cells. Cells were stimulated with 1α,25(OH)2D3 or the analogue 2a, each 
applied at their EC50-concentrations (6 x 10
-9
 M for 1α,25(OH)2D3 and 3 x 10
-9
 
M for analogue 2a). Open bars represent results for 1α,25(OH)2D3 and black 
bars for compound 2a. Bars represent means and S.D. of three independent 
experiments.  
Figure 4. Analogues 2a and 2b induce an adhesive epithelial phenotype in 
SW480-ADH cells. (A) Differentiation of SW480-ADH cells demonstrated by 
phase-contrast micrographs of cells treated with 10
-7
 M of each compound or 
vehicle for 48 h. A representative experiment is shown. (B) Western blot 
analysis of the expression of the expression of E-cadherin, VDR and -actin 
(loading control) at 8 h and 48 h of treatment with 10
-7
 M of each compound. 
Numbers show the quantification of the E-cadherin induction (ratio of levels in 
treated versus untreated cells) after normalization to -actin. A representative 
experiment is shown. 
 
Protein Data Bank Accession Number - The accession number for the 
coordinates of the complex reported in this article is PDB ID (3P8X) 
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Figure 1. Chemical structure of 1α,25(OH)2D3 and 20(17 18)-abeo-
analogues. 
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Figure 2. Conformation of the VDR-bound 2a analogue. 
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Figure 3. Transactivating potency of different VDR point mutants in COS-1 
cells.  
 
 
 
 
 
 
 
 
 
Figure 4. Analogues 2a and 2b induce an adhesive epithelial phenotype in 
SW480-ADH cells. 
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Scheme 1. Synthesis of 2a and 2b 
c
H
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H
d
O
e
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H
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HO
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OSiSiO
(O)PPh2
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4
O
H
4
HO
2a
Si = SiEt3 = TES
TBS = Si(t-Bu)Me2
7  
a
Key: (a) n-BuLi, THF, -78 ºC; 4.  (b) HF-pyridine, CH2Cl2, (c) LiAlH4, Et2O, 
; p-TsCl, DMAP, py, CH2Cl2, 0 ºC; NaCN, DMSO, 90 ºC; i-Bu2AlH, CH2Cl2, 
0 ºC; MeLi, Et2O; PDC, CH2Cl2; MeLi, Et2O. (d) 48% HF-Py, CH3CN, CH2Cl2, 
Et3N; H2, 5% Pd-C, EtOAc; PDC, CH2Cl2. (e) 3-Li-anion; HF-pyridine, CH2Cl2 
(12 steps from 5, 15.7% yield). 
 
 
 
 
 
 
 
Table 1. In vitro binding affinities and antiproliferative activities and in vivo 
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calcemic effects of 1α,25(OH)2D3 and its 20(17→18)-abeo-1α,25-dihydroxy-
21-norvitamin D3 analogues. 
 
1α,25(OH)2D
3 
compound 
2a 
compound 
2b 
DBP KD 5 x 10
8
 M
-1
 2 x 10
6
 M
-1
 4 x 10
-6
 M
-1
 
VDR KD 2 x 10
10
 M
-1
 2 x 10
9
 M
-1
 6 x 10
-9
 M
-1
 
Growth-inhibitory activity 
(EC50) 
6 x 10
-8
 M 5 x 10
-8
 M 2 x 10
-7
 M 
Calcemic activity (max 
applicable dose) 
0.1 µg/kg/day 
> 60 
µg/kg/day 
>100 
µg/kg/day 
The binding of 1α,25(OH)2D3 and the compounds 2a and 2b to human DBP 
and pig VDR was expressed by their dissociation constants. The 
antiproliferative effects of 1α,25(OH)2D3 and its analogues on MCF-7 cells 
were expressed as the concentrations required for the half-maximal inhibition 
of [
3
H]thymidine incorporation. The calcemic activity of 1α,25(OH)2D3 and 
analogues 2a and 2b was determined in mice by intraperitoneal injections 
during 7 consecutive days. This activity was expressed as the maximal dose 
that could be administered without exceeding a serum calcium concentration 
observed when mice were treated with 0.1 µg/kg/day 1α,25(OH)2D3.   
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